Summary of Conference Call Company and Industry - **Company**: Waters Corporation - **Industry**: Life Science Tools and Diagnostics Key Points and Arguments Business Overview - The CEO, Udit Batra, emphasized the strength of the acquired BD business, noting its strong brand recognition in flow cytometry and microbiology, with gross margins around 60% [4][5] - The integration of the BD business is ongoing, with a focus on improving execution and precision in operations [5][6] Q4 Performance - BD experienced an 11% decline in Q4, attributed to three non-recurring items and one recurring item, leading to flat growth when adjusted [10][11] - The recurring item, DRG headwinds in China, is expected to persist into the current year, impacting guidance [11][12] Future Guidance - For Q1, a decline of 2.5% is anticipated, with expectations of flat to low single-digit growth in Q2 and Q3, and low to mid-single-digit growth in Q4 [11][12] - The CEO expressed confidence in achieving EPS growth commitments despite current challenges [12] Bioscience Business - The bioscience business was down 10%, underperforming compared to market expectations, which should have been low to mid-single digits [15][16] - The CEO highlighted the need for improved precision in management and execution to address underperformance [23][24] Pricing Strategy - The bioscience business has been passing on only 0-50 basis points of pricing, which is below expectations given its differentiated portfolio [25][26] - The CEO emphasized the importance of focusing on pricing improvements and distribution strategies [25][26] Core Waters Business - The core Waters business is expected to grow organically at 6.25% in 2026, with strong performance in chemistry and service segments [32][36] - New product launches and improved service attachment rates are anticipated to drive growth [38][39] LC-MS Replacement Cycle - The LC-MS replacement cycle is expected to return to high single digits by mid-2027, with ongoing discussions about reshoring contributing to growth [41][46] Margin Expectations - BD's operating margin is projected to normalize around 22.4%, with cost adjustments and tariff implementations expected to contribute positively [72][86] - The CEO noted that pricing improvements are necessary to achieve desired margins, with current pricing at 50 basis points [86] Organizational Focus - The CEO plans to focus on specific business areas, particularly the reagents business, while ensuring accountability and support for teams [92][96] - Cross-pollination of successful strategies among teams is encouraged to enhance overall performance [96] Additional Important Content - The CEO highlighted the importance of precision in forecasting and execution, particularly in response to external challenges such as government shutdowns [14][23] - There is a strong emphasis on the engagement and energy within the organization, with a commitment to improving operational efficiencies and customer relationships [8][90]